Potassium Iodide

ApprovedSmall molecule

MMeda Pharmaceuticals

Potassium Iodide is one of 242 small molecule programs targeting Duodenal Ulcer. It is currently in Approved.

Indications

Total Trials

Active Trials

241

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Duodenal UlcerActive, not recruiting

Mitral RegurgitationActive, not recruiting

ThyroiditisActive, not recruiting

Eye DiseaseUnknown

UrolithiasisUnknown status

Anemia (phenotype)Unknown

HypertensionCompleted

Heart FailureActive, not recruiting

TreatmentRecruiting

Kidney StoneNot yet recruiting

Duodenal UlcerApproved

Active, not recruiting

Mitral RegurgitationPreclinical

Active, not recruiting

ThyroiditisPreclinical

Active, not recruiting

Eye DiseasePreclinical

Unknown

UrolithiasisApproved

Unknown status

Anemia (phenotype)Preclinical

Unknown

HypertensionApproved

Completed

Heart FailurePreclinical

Active, not recruiting

TreatmentApproved

Recruiting

Kidney StonePhase 1

Not yet recruiting

Showing 10 of 15 indications

Competition

Competitive Landscape

332 competitors in Treatment

#DrugCompanyPhaseTrials

Potassium Iodide

MMeda Pharmaceuticals

Approved

1 2

Biltricide

Bayer

Preclinical

3 3

Alfenta

Jazz Pharmaceuticals

Preclinical

1 4

Niclocide

Bayer

Preclinical

1 5

Minipress

Pfizer

Preclinical

1 6

Theo-Dur

Pfizer

Preclinical

1 7

Lamprene

Novartis

Preclinical

1 8

Emtriva

Gilead

Preclinical

1 9

Hivid

CConrado Roberto Hoffmann Filho

Preclinical

6 10

Intuniv

PPromius Pharma, LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

N/ANot yet recruiting

Women

NCT07202832

N/AActive, not recruiting

Study completion

NCT05389995

Q3 2027

Phase 1Not yet recruiting

Efficacy

NCT04651088

Q4 2027

Phase 1Not yet recruiting

Kidney Stone

NCT06819111

Q1 2028

Phase 1/2Not yet recruiting

Kidney Stones

NCT07408076

Clinical

Trials by Indication[1]

Kidney Stones2 trials

Effects of Potassium Citrate in Urine of Children With Elevated Calcium in Urine and Kidney Stones

Withdrawn·—·N/A·NCT00120731

Sodium Bicarbonate as an Alternative to Potassium Citrate for Kidney Stones

Not yet recruiting·UUniversity of California, Los Angeles·Phase 1/2·NCT07408076·30 enrolled

Terminated·UUniversity Hospital, Toulouse·Phase 3·NCT00379535·374 enrolled

High Blood Pressure1 trial

Dietary Counseling or Potassium Supplement to Increase Potassium Intake in Patients With High Blood Pressure

Completed·OOttawa Hospital Research Institute·Phase 3·NCT03809884·7 enrolled

24 more indications

Calcinosis1 trial

Study to Assess the Efficacy and Safety of Oral Potassium Citrate on the Prevention of Nephrocalcinosis in Extreme Premature

Unknown status·JJuan A. Arnaiz·Phase 3·NCT01756547·74 enrolled

Hypercalciuria1 trial

Phase III Randomized, Double-Blind Study of Potassium Phosphate Vs Potassium Citrate for Absorptive Hypercalciuria

Completed·NNational Center for Research Resources (NCRR)·Phase 3·NCT00004284·300 enrolled

Treatment1 trial

Exploratory Study on the Treatment of Gout With Potassium Citrate Sustained-release Tablets

Recruiting·HHuashan Hospital·Phase 4·NCT06966635·312 enrolled

Kidney Stone1 trial

Role of Medication in Making Urine Less Acidic as Part of Kidney Stone Prevention

Not yet recruiting·UUniversity of Texas Southwestern Medical Center·Phase 1·NCT06819111·20 enrolled

Clinical Trial1 trial

A Randomized Clinical Trial to Evaluate the Effectiveness of Oral Potassium Citrate in Preventing Ureteral Stent Encrustation in Patients Undergoing Ureteroscopy for Uric Acid Kidney Stones

Active, not recruiting·ZZagazig University·Phase 2/3·NCT06819553·48 enrolled

Bone1 trial

Effect of Neutralization of Endogenous Acid Production on BMD and Bone Microarchitectural

Completed·KKantonsspital Baselland Bruderholz·Phase 3·NCT00509405·202 enrolled

Heart Failure1 trial

Study of Drug Therapy for Pediatric Heart Failure

Unknown status·CChina National Center for Cardiovascular Diseases··NCT06039540·200 enrolled

Ventricular Function1 trial

Study of Innovative Drug Strategies in Improving Left Ventricular Function After Mitral Repair

Unknown status·CChina National Center for Cardiovascular Diseases··NCT06039592·164 enrolled

Mitral regurgitation1 trial

Study of Innovative Drug Treatment Therapy for Pediatric Mitral Regurgitation

Unknown status·CChina National Center for Cardiovascular Diseases··NCT06037434·122 enrolled

Duodenal Ulcer1 trial

The Efficacy and Safety of Ilaprazole/Doxycycline-based Bismuth-containing Quadruple Therapy on Hp Infected Duodenal Ulcers

Completed·TThe Third Xiangya Hospital of Central South University·Phase 4·NCT03342456·184 enrolled

Metabolic Acidosis1 trial

Metabolic Acidosis in Renal Transplant Patients

Completed·UUniversity of Zurich·Phase 2·NCT00913796·30 enrolled

Uric Acid1 trial

Impact of Sodium Bicarbonate on 24-hour Urine Parameters in Hypocitriuric and Uric Acid Stone Formers

Recruiting·UUniversity of California, Irvine·Phase 1·NCT06335537·100 enrolled

Efficacy1 trial

Comparing Alkalinizing Agents Efficacy on Stone Risk in Patients on a Metabolically Controlled Diet

Not yet recruiting·UUniversity of Texas Southwestern Medical Center·Phase 1·NCT04651088·15 enrolled

Women1 trial

Urine Alkalinization for UTI in Women: RCT

Not yet recruiting·—·N/A·NCT07202832·50 enrolled

Side Effects1 trial

Preventing Metabolic Side Effects of Thiazide Diuretics With KMgCitrate

Completed·UUniversity of Texas Southwestern Medical Center·N/A·NCT02665117·61 enrolled

Metabolism1 trial

The Effects of Potassium Citrate on Bone Metabolism

Completed·WWeill Medical College of Cornell University·Phase 4·NCT00357331·83 enrolled

Hyperthyroidism1 trial

Effective Iodide Therapy for Untreated Patients With Graves' Hyperthyroidism Avoiding Thionamide Drugs With Many Side Effects

Completed·KKyushu University··NCT04686006·504 enrolled

Graves disease1 trial

Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease

Completed·UUniversity of Massachusetts, Worcester·Phase 4·NCT00946296·36 enrolled

Relapsed/Refractory1 trial

Phase 2 Study of Bexxar in Relapsed/Refractory DLCL

Completed·SSusan Knox·Phase 2·NCT00490009·9 enrolled

Radiation Therapy1 trial

Study of Bexxar <Tositumomab> Combined With External Beam Radiation Therapy

Terminated·SStanford University·Phase 2·NCT00490490·8 enrolled

Thyroid1 trial

Measurement of Iodolipids in the Thyroid Gland and Other Biological Samples

Unknown status·—·N/A·NCT05628506·20 enrolled

Urolithiasis1 trial

A Study on the Effection of Potassium Citrate Extended-release Tablets on Urolithiasis Formation or Recurrence

Unknown status·DDawnrays Pharmaceutical (Holdings) Limited·Phase 4·NCT03007160·2,001 enrolled

Chronic Kidney Diseases1 trial

Bone in CKD Alkali Response Pilot Trial (BICARb)

Terminated·AAlbert Einstein College of Medicine·Preclinical·NCT05918029·6 enrolled

Unspecified3 trials

Hydroxycitrate: A Novel Therapy for Calcium Phosphate Urinary Stones

Recruiting·UUniversity of Texas Southwestern Medical Center·Phase 4·NCT06003348·25 enrolled

Potassium Citrate and Crystal Light Lemonade

Active, not recruiting·NNorthwestern University·N/A·NCT05389995·10 enrolled

MIBG With Dinutuximab +/- Vorinostat

Completed·NNew Approaches to Neuroblastoma Therapy Consortium·Phase 1·NCT03332667·45 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

THYRO-BLOCK

NDA NDA018307

Feb 19, 1982

POTASSIUM IODIDE

NDA NDA018551

May 12, 2011

IOSAT

NDA NDA018664

Sources

References

[1]
ClinicalTrials.gov — 34 trial records for Potassium Iodide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Potassium Iodide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Potassium Iodide. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA018664). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Meda Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: MMeda Pharmaceuticals

Potassium Iodide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q3 2027

Q4 2027

Q1 2028

Trials by Indication[1]

Kidney Stones2 trials

Neuroblastoma2 trials

Hypertension2 trials

Pregnancy1 trial

High Blood Pressure1 trial

Calcinosis1 trial

Hypercalciuria1 trial

Treatment1 trial

Kidney Stone1 trial

Clinical Trial1 trial

Bone1 trial

Heart Failure1 trial

Ventricular Function1 trial

Mitral regurgitation1 trial

Duodenal Ulcer1 trial

Metabolic Acidosis1 trial

Uric Acid1 trial

Efficacy1 trial

Women1 trial

Side Effects1 trial

Metabolism1 trial

Hyperthyroidism1 trial

Graves disease1 trial

Relapsed/Refractory1 trial

Radiation Therapy1 trial

Thyroid1 trial

Urolithiasis1 trial

Chronic Kidney Diseases1 trial

Unspecified3 trials

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News